In Situ Forming Systems (Depots)

Wright, Jeremy C.; Sekar, Michael M. A.; Osdol, William van; Su, Huey Ching; Miksztal, Andrew R.

doi:10.1007/978-1-4614-0554-2_9

Cited by 3 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blends of block copolymers and PLGA are also effective in offering prolonged release of protein drug. Injectable in situ -forming depot systems, including those based on injectable solutions of PLGA in sucrose acetate isobutyrate 40,41 or N -methyl pyrollidone 42,43 , offer similar potential benefits 44 .…”

Section: Advanced Formulations and Chemistrymentioning

confidence: 99%

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies

Mitragotri

Burke

Langer

2014

Nat Rev Drug Discov

1,386

1,037

View full text Add to dashboard Cite

The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies and recombinant proteins, poses substantial challenges owing to their large size and susceptibility to degradation. In this Review we highlight recent advances in formulation and delivery strategies — such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs — and discuss their advantages and limitations. We also highlight current and emerging delivery routes that provide an alternative to injection, including transdermal, oral and pulmonary delivery routes. In addition, the potential of targeted and intracellular protein delivery is discussed.

show abstract

Section: Advanced Formulations and Chemistrymentioning

confidence: 99%

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies

Mitragotri

Burke

Langer

2014

Nat Rev Drug Discov

1,386

1,037

View full text Add to dashboard Cite

show abstract

“…Clinical studies demonstrated a 22.5 mg leuprolide depot maintained an effective suppression of serum testosterone (50 ng/dL) for more than 3 months. [10]…”

Section: Potential Of Novel Therapies Enabled By Smart Nanocarriersmentioning

confidence: 99%

“…Chemically distinct drugs like porcine growth hormone and glucagon-like peptide-1 (GLP-1) may be incorporated, one at a time, and released from ReGel®. [10]…”

Section: Potential Of Novel Therapies Enabled By Smart Nanocarriersmentioning

confidence: 99%

Treatment for uterine fibroids: Searching for effective drug therapies

Taylor

Leppert

2012

Drug Discovery Today: Therapeutic Strategies

View full text Add to dashboard Cite

Uterine fibroids are common reproductive-age benign tumors that contribute to severe morbidity and infertility. Cumulative incidence is 4 times higher in Africian-Americans compared to Caucasians and constitutes a major health disparity challenge. Fibroids are the leading indication for hysterectomy and their management averages $21 billion annually in the US. No long term minimally invasive therapies exist. Thus, promising drug therapies, their chemistry, pharmacology, and clinical efficacy, focusing first on innovative drug delivery approaches, are reviewed.

show abstract

“…LADDS have been shown to prolong drug release from several hours up to 3 years depending on characteristics of the drug, disease and delivery system [2,3]. LADDS include oral sustained release systems, injectable implants, in situ forming implants, inserts, wafers, transdermal patches, microspheres and nanoparticles [1,4,5]. A number of potential drug classes could be good candidates for LADDS: these include pain killers, biopharmaceuticals, anticancer drugs and centrally acting drugs [2,6].…”

Section: Introductionmentioning

confidence: 99%